Glucagon Review: Evidence, FDA Status, Uses & Risks

Glucagon Review: Evidence, FDA Status, Uses & Risks

Glucagon evidence, regulatory status, intended use, known risks, and limitations.

Regulatory status

FDA-approved in multiple product-specific forms

Quick verdict

An evidence-backed prescription option for its specific FDA-approved indication. Individual decisions require a licensed clinician.

At a glance

Primary use: Emergency treatment of severe hypoglycemia; other uses depend on product. Evidence strength: Strong — FDA-reviewed product-specific evidence. Prescription treatment and clinician supervision are required.

What it is

Glucagon is a peptide hormone used in approved products, including emergency treatments for severe hypoglycemia.

What it’s used for

Emergency treatment of severe hypoglycemia; other uses depend on product

How it works

Mechanism and pharmacology are described in the current FDA prescribing information; this review does not provide dosing instructions.

Clinical evidence

Strong — FDA-reviewed product-specific evidence. Public claims on this page are limited to the cited regulatory and clinical evidence.

FDA / Regulatory status

FDA-approved in multiple product-specific forms

Administration

Nasal powder or subcutaneous/intramuscular injection, depending on product. Prescription required. Multiple FDA-approved presentations include nasal and ready-to-use or reconstituted injection products. Coverage, copays, availability, and replacement timing vary. FDA records confirm an approved generic glucagon emergency kit; actual pharmacy stock should be checked. No single consumer out-of-pocket cost is assumed.

Potential benefits

FDA-reviewed evidence supports product-specific benefits for labeled indications.

Known risks & side effects

Warnings and contraindications vary by product and can include hypersensitivity, pheochromocytoma, and insulinoma considerations.

Contraindications / Important warnings

Warnings and contraindications vary by product and can include hypersensitivity, pheochromocytoma, and insulinoma considerations.

Who it may be appropriate for

Potentially appropriate only for patients who meet product-specific labeled criteria after clinician assessment.

Evidence gaps

Users and caregivers should follow the specific approved product labeling.

Alternatives

Review established options for the relevant goal and discuss clinically appropriate alternatives with a licensed professional.

Score breakdown

Editorial score 9.1/10 — Clinical Evidence 9.5; Regulatory Status 10; Effectiveness Evidence 9; Safety / Known Risks 8; Access & Convenience 9; Cost Transparency 7.5. Weighted using the published methodology.

Final verdict

A legitimate prescription therapy for specific approved uses, with important product-specific risks and limitations.

MyPeptideQuest

Information only. Not medical advice. No dosing or self-treatment instructions are provided.